A systematic literature review of the burden of pediatric multiple sclerosis in North America and Europe

**CURRENT STATUS:** POSTED

Lauren B. Krupp  
NYU Langone Medical Center

Joseph Goble  
Baylor Scott & White Health

Michel A. Kroes  
Novartis Pharmaceuticals UK Limited

Haley Toledano  
Novartis Pharmaceuticals Corporation

Melissa Thompson  
Cornerstone Research Group

mthompson@cornerstone-research.com **Corresponding Author**

Nabeel Pervaiz  
Cornerstone Research Group Inc.

Maria Cecilia Vieira  
Novartis Pharmaceuticals Corporation

**DOI:**  
10.21203/rs.2.9728/v1

**SUBJECT AREAS**  
Neurology

**KEYWORDS**  
Multiple sclerosis, Pediatric, Children, Burden, Quality of Life, Epidemiology, North America, Europe
Abstract

Background: Multiple sclerosis (MS) is a chronic neurodegenerative condition that severely impacts patient functioning and quality of life (QoL). Onset of MS typically occurs in adults and evidence is growing for onset in children and adolescents. Several studies describe the clinical burden of pediatric MS; however, to date, no systematic literature review summarizing the clinical burden of pediatric MS has been published. Objective: To conduct a systematic literature review to identify published data on the epidemiology, disease characteristics, QoL, and economic burden of pediatric MS in North America and Europe. Methods: Systematic searches were conducted in Ovid MEDLINE®, Embase, and Cochrane library to identify studies that enrolled patients with pediatric MS and reported at least one outcome related to the epidemiological, humanistic, and economic burden of pediatric MS. Only English-language studies were included. Results: In total, 7,447 unique records were identified, of which 103 met the study’s inclusion criteria. Of the included articles, 9 reported incidence and prevalence, 39 reported relapse rates, 15 reported QoL, 22 reported fatigue, 37 reported cognitive function, and 17 reported school performance. Incidence of pediatric MS ranged from 0.30 to 2.64 per 100,000 person-years, with few studies suggesting that incidence may increase with age. Prevalence was reported as high as 14.6 cases per 100,000 persons in the USA and 9.6% of all MS patients in European countries. The range of annualized relapse rates was similar across countries, at 0.36-2.76 in North America and 0.65-1.11 in European countries. Patients with pediatric MS experienced reduced QoL compared to healthy controls. Patients experienced reduced diminished cognitive functioning, worse school performance and increased fatigue. Limited information was identified for the mortality and economic burden of pediatric MS. Conclusions: Several studies describe the clinical burden of pediatric MS. Although incidence and prevalence rates for the disease are relatively low, the rate of relapse and burden to patients is considerable. Further studies are required to address gaps in the understanding of prognostic factors for relapse and the impact of QoL, fatigue, and cognitive function. Additional research on mortality and economic outcomes will be important to guide treatment pathways and reimbursement decisions.

Background
Multiple sclerosis (MS) is a chronic neurodegenerative condition that affects >2.3 million people worldwide, with onset commonly occurring in adults (1-3). However, evidence shows that MS can occur in children, with 3%-5% of all MS patients younger than 16 years old at onset and <1% of patients under the age of 10 (2). Children with MS experience symptoms such as numbness, tingling and weakness, walking difficulties, dizziness, fatigue, visual blurring, and occasionally double vision (3, 4).

Several studies have been published that describe the clinical burden of pediatric MS; however, to date, no systematic literature review has been conducted to summarize the current evidence. Thus, the primary objective of the current study was to conduct a systematic literature review to identify data on the epidemiology, disease characteristics, quality of life (QoL), and economic burden of pediatric MS with a focus on the United States of America (USA). A secondary objective was to identify gaps to provide direction for future research in this field.

Methods

The systematic literature review adhered to the selection and reporting guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist (5).

Search Strategy

The search strategy was developed and tested through an iterative process by an experienced information specialist using the Peer Review of Electronic Search Strategies (PRESS) checklist and was peer reviewed by a senior information specialist (6) [see Additional File 1].

Using the OVID platform, the Ovid MEDLINE® (including Epub Ahead of Print and In-Process & Other Non-Indexed Citations) and Embase databases were searched. The Cochrane Library on Wiley was also used to search review and economic databases (i.e., Cochrane Database of Systematic Reviews, the Database of Abstracts of Review of Effects [DARE], Healthy Technology Assessment [HTA] Database, and the National Health Services Economic Evaluation Database [NHS EED]). The searches used a combination of controlled vocabulary (e.g., “Multiple Sclerosis”, “Epidemiologic Factors”, “Quality of Life”) and keywords (e.g., “RRMS”, “epidemiology”, “QoL”). Results were limited to English-language articles. All searches were performed on December 3, 2017. During screening, the
literature search protocol was modified ad-hoc to include European publications to increase comprehensiveness.

Selection Criteria

The inclusion and exclusion criteria are presented separately under the following headings: population, intervention, comparator, outcome, and study design (PICOS) in Table 1. Eligibility criteria were developed and used to screen all identified studies. Eligible studies included pediatric patients (<18 years old) with MS in North America and Europe that reported at least one outcome related to the clinical burden, humanistic burden, and economic burden of pediatric MS (a full list is provided in Table 1). All included studies were published full-text observational studies, narrative reviews, systematic reviews and meta-analyses; conference abstracts were included.

Study Selection

A single reviewer screened citation titles and abstracts to assess study eligibility based on the predefined criteria. Eligible studies were reviewed in full-text by the same reviewer. Hand searches of relevant systematic reviews and meta-analyses were also performed to ensure no studies were missed. Reasons for study exclusion were documented (Figure 1).

Data Extraction and Quality Assessment

Data from eligible studies were collected using pre-specified data extraction forms for each sub-topic of interest. The information extracted from each study is summarized below.

Study Characteristics: Study design, region, study center/database, study year/period, study inclusion/exclusion criteria, number of included patients with pediatric MS, availability of follow-up data for patients ≥18 years old.

Patient Characteristics: Age, sex or gender, age at symptom onset, time since symptom onset, age at diagnosis, time since diagnosis, time between symptom onset and diagnosis, expanded disability status score (EDSS) (or other measure of disability) at baseline/timepoint of interest, treatment
status.

**Outcomes:** Incidence and prevalence rates for pediatric MS, number of relapses, annual relapse rates, QoL measures, fatigue measures, cognitive function measures, school performance measures. Data were extracted by a single reviewer. Comprehensive identification of the available data was priority; therefore, studies were not qualitatively assessed/rated in detail.

**Results**

A total of 7,565 records were identified through the database searches. After de-duplication, 7,447 unique records were selected for title and abstract review. After assessing all records based on title and abstract, 258 records were selected to be reviewed in full-text format. Of these records, 103 were found to fulfill the inclusion criteria. Results of each stage of the screening process are presented in **Figure 1.** Of the included articles, 9 (8.7%) examined epidemiological metrics (incidence, prevalence), 47 (45.6%) evaluated disease characteristics (disease course, relapse rate, disability, comorbidities), 52 (50.5%) investigated effects on daily living (QoL, mood, etc.), and 4 (3.9%) reported direct healthcare cost or resource use (**Figure 2**).

**Epidemiology**

**Incidence**

The systematic literature review identified nine studies that reported on the incidence of pediatric MS. Only one of these studies estimated the incidence of pediatric MS in the USA, reporting 0.57 cases per 100,000 children and adolescents in the state of Utah (**Table 2**)(7). Eight studies reported incidence rates for specific countries within Europe (8-15). In the most commonly reported age group, 0- to 15-year-olds, incidence rates ranged from 0.3 (16) to 0.64 (17) per 100,000 person-years. The incidence of pediatric MS increased with age, reaching a high of 2.64 per 100,000 person-years among 14- to 15-year-olds in one German nationwide surveillance study(17).

**Prevalence**

Prevalence rates for pediatric MS were reported in nine of the included studies(7, 8, 19-25). Three
studies reported rates in the USA(7, 19, 20), providing the number of cases per 100,000 persons. Across these studies, prevalence rates ranged from 0.035 to 14.6 cases per 100,000 persons, with the highest rate reported for patients aged 15 to 19 years. Six studies reported prevalence rates for pediatric MS for specific countries in Europe(8, 21-25), all of which reported rates as a percentage of all MS patients. The estimated prevalence of pediatric MS across European countries ranged from 0.7% to 9.6% of all MS patients. In all studies that reported prevalence by age group, higher rates were reported for older age groups than for younger age groups.

**Disease Characteristics**

**Relapse Rates**

Twenty-two publications were identified that reported relapse rates and/or the number of relapses in the past year experienced among North American patients with pediatric MS (see Additional File 2). Seventeen publications reported continuous measures, mostly in the form of annualized relapse rates (ARR). ARRs ranged from a low of 0.36 ± 0.16(29) to a high of 2.76(30). The highest rate was noted for the pediatric-onset population (≤18 years old) in the pre-treatment period. Post-treatment ARR was lower in the study that compared pre- and post-treatment ARR (30). In addition, relapse rates were highest in the early course of the disease decreasing with increasing disease duration (30-32).

Similar trends were observed in the European studies. Twenty-one publications were identified that reported relapse rates for European pediatric patients with MS (see Additional File 2). Eleven publications reported continuous measures; these were mostly in the form of ARRs and ranged from 0.65(33, 34) to 1.8 (35). Two studies reported relapse rates over 5 years after disease manifestation (36, 37). The highest relapse rate was 2.1 and was reported in Year 1 for patients with pediatric MS who were younger than 11 years of age(37). When Year 1 and Year 2 relapse rates were compared, the rates were always lower in Year 2. In addition, one study conducted a subgroup analysis comparing outcomes among ≤11-year-old and 14- to 16-year-old patients. In both Year 1 and Year 2, the 14- to 16-year-old sub-group had a lower relapse rate than the ≤11 year-olds (37). Overall, the results of the European studies were in alignment with those of the North American studies, showing
higher relapse rates among younger patients.

Three studies compared relapse rates amongst pediatric and adult patients with MS, finding that ARRs were consistently higher among pediatric patients(30, 38, 39). As expected, for both the pediatric and the adult population, ARRs were higher before treatment (2.76; 1.78) than after treatment (1.12; 0.35). In addition, another study concluded that relapse rates were more frequent early in the disease and became infrequent or absent over time (40). Overall, the results showed higher rates and number of relapses in the past year in younger patients and in the pre-treatment period, highlighting the importance of early diagnosis and treatment.

**Humanistic Burden**

**Quality of Life**

Ten studies reported QoL outcomes among North American patients with pediatric MS(41-50) (see Additional File 3). The most frequently used scale for assessment of QoL was the Pediatric Quality of Life Inventory (PedsQL); other scales included the Short Form-36 (SF-36) and Child Health Questionnaires (CHQ). Although several studies included the PedsQL, various versions were used or results from different domains were reported, thereby complicating the ability to make comparisons across the studies. Four studies compared the outcomes of patients with pediatric MS to those of healthy controls (42, 46, 47, 49). Three of these studies found that QoL was reduced in patients with pediatric MS compared with QOL in healthy controls(46, 47, 51), with two reporting significant differences(46, 47). Whereas one study reported that patients with pediatric MS have a similar QOL as the healthy population(52). Only one publication compared QoL between pediatric and adult patients with MS, finding no significant difference between groups(50).

Five studies reported QoL outcomes among European patients with pediatric MS (see Additional File 3) using various scales for assessment, including SF-36, PedsQL, and CHQ. Three studies compared outcomes among patients and healthy controls(53-55), reporting reduced QoL for children with MS; the reductions were significant in two studies. One of these studies compared the self-reported QoL scores of patients with those of their parents, while another only presented parent-reported scores(53, 55). All of the studies concluded that the QoL of both patients and their families is
negatively impacted by the physical and cognitive manifestations of MS (53-55).

Fatigue

Thirteen studies reported fatigue outcomes among North American patients with pediatric MS using a variety of measures (see Additional File 4). The most common assessment tool was the PedsQL Multidimensional Fatigue Scale (PedsQL MFS), which was used in three studies. In addition, three studies compared pediatric MS patients with healthy controls reporting higher fatigue scores in pediatric MS patients in various assessment tools (49, 56, 57). Furthermore, one study compared fatigue outcomes among patients with MS or with monophasic acquired demyelinating syndrome, finding that patients with MS reported higher levels of general and total fatigue (58). Another study compared fatigue between pediatric and adult MS patients and observed no significant differences between groups (59).

Ten studies reported fatigue-related outcomes among European patients with pediatric MS (see Additional File 4). Nine of these publications reported categorical outcomes, most of which assessed the percentage of patients experiencing fatigue, which ranged from 20% (60, 61) to as high as 79.5% (38). Two publications reported continuous outcomes using either the Checklist Individual Strength fatigue score or the PedsQL MFS. These studies reported that patients with pediatric MS experience significantly worse fatigue than healthy controls. Overall, the results of the European studies were similar to those from the North American studies, highlighting fatigue as a common symptom experienced by patients with pediatric MS.

Cognitive Function

A variety of measures were used for evaluation, including the Expressive One-Word Picture Vocabulary Test (EOWPVT), the Symbol Digit Modalities Test (SDMT), and the Wechsler Abbreviated Scale of Intelligence (WASI). Cognitive function tests included but were not limited to assessments of learning, memory, information processing speed, attention, language, and executive functioning.

Twenty-six studies reported cognitive function outcomes among North American patients with pediatric MS (41-45, 50, 56, 57, 62-72) (see Additional File 5). Ten publications compared outcomes among patients with those of healthy controls and presented the number and percentage of
cognitively impaired children or those with below-average scores on several cognitive performance scales (32, 59, 73-80). In these studies, the percentage of patients with cognitive impairment ranged from 32% to 35%. Further, cognitive performance was reduced among patients with pediatric MS compared with healthy children, with five reporting statistical significance (63, 76, 80-82). In particular, patients with MS had lower scores in processing speed, visuomotor speed, and executive control. One publication compared outcomes among patients with pediatric-onset MS and those with adult-onset MS, finding that patients with pediatric-onset MS had a lower mean cognitive performance measure than patients with adult-onset MS (59).

Ten studies reported cognitive function outcomes among European patients with pediatric MS (see Additional File 5). Four publications compared outcomes with healthy controls and all four reported reduced IQ or lower performance on various cognitive tests in patients with MS compared to healthy controls (83-86). One study reported that the cognitive impairment associated with pediatric MS deteriorates over time (83). Two studies included patients with adult MS as a comparator; one of these studies found that patients with pediatric-onset MS are at a higher risk of developing cognitive impairment in adulthood than patients with adult-onset MS (38). Across studies, the percentage of patients with pediatric MS and cognitive impairment ranged between 18% and 70% (37, 85-89).

School Performance

Finally, 11 studies reported school performance outcomes among North American patients with pediatric MS (see Additional File 6). Most of these publications reported varying indicators of reduced academic performance or difficulties in school. One study reported that 35.1% of patients with MS needed assistance with school work and a change in school curriculum. Two publications compared school performance results with those of healthy controls, with one finding that academic difficulties were increased in patients with pediatric MS (90). Seven publications reported outcomes relating to school performance among European patients with pediatric MS (37, 86, 87, 91-94) (see Additional File 6). Of these studies, three reported that 10% of patients required support from a teacher because of cognitive difficulties. No comparisons were made between patients and healthy controls.
Discussion
Multiple sclerosis has typically been characterized as an adult-onset disease, but evidence shows an increasing awareness of onset in children. Thus, a systematic literature review was conducted to understand the clinical burden of pediatric MS and to identify gaps in current knowledge. Overall, evidence varied across studies. Incidence of pediatric MS ranged from 0.30 to 2.64 per 100,000 person-years, with few studies suggesting that incidence may increase with age (12, 13). Prevalence was reported as high as 14.6 cases per 100,000 persons in the USA (19) and 9.6% of all MS patients in Europe (25). Annualized relapse rates were similar across countries, at 0.36-2.76 in North America and 0.65-1.11 in European countries (see Additional File 2). Some studies suggested that QoL, fatigue, cognitive impairment, and school performance is poor in patients with pediatric MS (see Additional Files 3-6).

Incidence and prevalence rates of pediatric MS were primarily reported for European countries, with only one publication reporting incidence and three reporting prevalence in the USA. Rates reported were region-specific; for example, data from the USA study was representative of only Utah (7), only one European study reported countrywide data (13), and the remaining European studies reported regional data. The incidence and prevalence of pediatric MS varied across countries; however, results were not uniformly reported, preventing meaningful comparisons between the USA and European countries. A paucity of studies from USA and Central Europe were found creating difficulty understanding the regional differences in incidence. Additional data are required to understand if regional differences exist.

Many studies identified reported ARRs of pediatric MS in both North America and Europe, with 8 from Canada, 14 from the USA, and 21 from European countries. The highest ARR in North America was reported to be 2.76 in a pediatric-onset cohort that had an average age of 15 years (30). In contrast, the highest ARR in Europe was reported to be 1.1 in patients ≤11 years old (37). Emerging evidence suggests that relapse rates may be higher among patients with pediatric MS than those with adult-onset MS (30, 39, 95). In one study, relapse rates were also noted to be higher among children younger than 11 years old than among those 14-16 years old (37). Additionally, one study reported
higher relapse rates before treatment than after treatment (30). Further study of the prognostic factors influencing relapse of pediatric MS are needed to define the importance of early diagnosis and treatment of this disease.

Many studies were found reporting measures for QoL, fatigue, cognitive function, and school performance, with at least 5 publications identified from North America and Europe in each category. As publications typically used different scales to measure relevant outcomes, particularly for QoL and cognitive function, this precluded meaningful comparisons of these outcomes across studies. Evidence comparing QoL (see Additional File 3), fatigue (see Additional File 4), and cognitive function (see Additional File 5) between patients with pediatric MS and health controls reported reductions, with approximately half of these studies reporting statistically significant reductions in patients with pediatric MS. These results were consistent between North American and European studies. Furthermore, emerging evidence suggests that these outcomes in pediatric MS were similar those reported in adult-onset MS (30, 39, 50, 95). Conflicting data were reported on academic performance or difficulties in schools in patients with pediatric MS, necessitating the need for further investigation.

Evidence for mortality and economic burden of pediatric MS was extremely limited. These areas represent opportunities for further study and will be important to guide treatment pathways and reimbursement decisions.

To the best of our knowledge, this is the first systematic literature review to investigate the totality of evidence on the clinical, humanistic, and economic burden of pediatric MS. The systematic search strategy was developed by an information specialist and adhered to the PRESS checklist. Searches were conducted in multiple databases to ensure all relevant studies were identified.

An inherent limitation of the current study is the generalizability of the data to pediatric patients with MS, given the evolving changes in diagnosis criteria(96). In addition, this review followed a pre-specified protocol to examine the burden of MS in a North American pediatric population; however, during the screening process, the protocol was modified ad-hoc to include European publications to increase comprehensiveness. This resulted in a larger number of studies (N = 7,565) being identified.
than originally expected. As a result, the study screening was not conducted in duplicate, and quality was not systematically assessed. However, this approach is often taken when conducting systematic literature reviews that are broad in scope and expected to produce a large number of hits. Also, the decision to limit the search to English-language publications may have resulted in bias towards publications from English-speaking countries, especially among those included from Europe.

Conclusions
To our knowledge, this is the first comprehensive literature review of the burden of pediatric MS in both North America and Europe. Although incidence and prevalence rates for the disease are relatively low, the rate of relapse and burden to patients may be considerable. Further study is required to address gaps in the understanding of prognostic factors for relapse and the impact of QoL, fatigue, and cognitive function. Additional research on mortality and economic outcomes will be important to guide treatment pathways and reimbursement decisions.

Abbreviations
ARR Annualized Relapsed Rate
CHQ Child Health Questionnaires
DARE Database of Abstracts of Review of Effects
EDSS Expanded Disability Status Score
EOWPVT Expressive One-Word Picture Vocabulary Test
HTA Healthy Technology Assessment
MFS Multidimensional Fatigue Scale
MS Multiple Sclerosis
NHS EED National Health Services Economic Evaluation Database
PedsQL Pediatric Quality of Life Inventory
PICOS Population, Intervention, Comparator, Outcome, and Study design
PRESS Peer Review of Electronic Search Strategies
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analysis
QoL Quality of Life
SDMT Symbol Digit Modalities Test
SF-36 Short Form-36 Item Questionnaire
USA United States of America
WASI Wechsler Abbreviated Scale of Intelligence

Declarations
Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and materials: The datasets used during the current study are available from the corresponding author on reasonable request.

Competing interests: Cornerstone received financial support from Novartis for the conduct of this study. Michel A. Kroes, Haley Toledano, are employees of Novartis. Maria Cecilia Vieira was an employee of NPC when the study was conducted. Nabeel Pervaiz was an employee of Cornerstone when the study was conducted. Melissa Thompson is an employee and shareholder of Cornerstone
Research Group Inc. Joseph Goble was a fellow at Novartis Pharmaceuticals Corporation when the study was conducted.

**Funding:** This study was funded by Novartis Pharmaceutical Corporation.

**Authors’ contributions:** Michel A. Kroes, Haley Toledano, Joseph Goble, Maria Cecilia Vieira were involved in conceptualization of the study and interpretation of the results and review and approval of the final manuscript. Melissa Thompson and Nabeel Pervaiz were consultants who executed the study.

**Acknowledgements:** We would like to acknowledge contribution of Hannah Guiang who served as a medical writer for writing and editing this manuscript.

**References**

1. Society NM. Multiple Sclerosis FAQs [Available from: https://www.nationalmssociety.org/What-is-MS/MS-FAQ-s.

2. Boiko A, Vorobeychik G, Paty, D, et al. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59(7):1006-10.

3. Wynia K, Middel B, Van Dijk J, De Keyser J, Reijneveld S. The impact of disabilities on quality of life in people with multiple sclerosis. Multiple Sclerosis Journal. 2008;14(7):972-80.

4. Clinic C. Pediatric Multiple Sclerosis: Symptoms [Available from: https://my.clevelandclinic.org/health/diseases/17337-pediatric-multiple-sclerosis/symptoms.

5. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009;339:b2535.

6. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. Journal of clinical epidemiology. 2016;75:40-6.

7. Wright M A, Korgenski EK, Bardsley T, et al. Comprehensive population-based
determination of pediatric multiple sclerosis health care costs. Neurol Neuroimmunol Neuroinflamm. 2017;4(1):e314, 2017.

8. Manouchehrinia A, Beiki O, Kavaliunas A, Ramanujam R, Glaser A, Hillert J. Clinical course of childhood-onset multiple sclerosis: Results from the Swedish multiple sclerosis register. Multiple sclerosis (Houndmills, Basingstoke, England). 2015;Conference:(var.pagings). 23 (11 Suppl 1):94-5.

9. Blinkenberg M, Koch HN. The incidence of childhood multiple sclerosis in Denmark. A nationwide register study. Multiple sclerosis (Houndmills, Basingstoke, England). 2013;Conference:(var.pagings). 19 (11 Suppl 1):95.

10. Dell’Avvento S, Sotgiu MA, Manca S, et al. Epidemiology of multiple sclerosis in the pediatric population of Sardinia, Italy. Eur J Pediatr. 2016;175(1):19-29.

11. Gudbjornsson BT, Haraldsson A, Einarsdottir H, et al. Nationwide Incidence of Acquired Central Nervous System Demyelination in Icelandic Children. PediatrNeurol. 2015;53(6):503-7.

12. Pohl D, Hennemuth I, von Kries R, et al. Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey. Eur J Pediatr. 2007;166(5):405-12.

13. Reinhardt K, Weiss S, Rosenbauer J, Gartner J, von KR. Multiple sclerosis in children and adolescents: incidence and clinical picture - new insights from the nationwide German surveillance (2009-2011). Eur J Neurol. 2014;21(4):654-9.

14. Bizjak N, Osredkar D, Benedik MP, et al. Epidemiological and clinical characteristics of multiple sclerosis in paediatric population in Slovenia: A descriptive nation-wide study. Mult Scler Relat Disord. 2017;18:56-9.

15. Boesen MS, Magyari M, Koch HN, et al. Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during
1977-2015: A nationwide population-based incidence study. Multiple sclerosis (Houndmills, Basingstoke, England). 2017;:1352458517713669, 2017 Jun 01.

16. Pohl, D. Epidemiology, immunopathogenesis and management of pediatric central nervous system inflammatory demyelinating conditions. Current Opinion in Neurology. 2008;21(3):366-72.

17. Reinhardt K, Weiss S, Rosenbauer J, et al. Multiple sclerosis in children and adolescents: incidence and clinical picture - new insights from the nationwide German surveillance (2009-2011). Eur J Neurol. 2014;21(4):654-9.

18. Manouchehrinia, A, Beiki O, Kavaliunas A, et al. Clinical course of childhood-onset multiple sclerosis: Results from the Swedish multiple sclerosis register. Multiple sclerosis (Houndmills, Basingstoke, England). 2015;Conference:(var.pagings). 23 (11 Suppl 1):94-5.

19. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86(11):1014-21.

20. Lavery AM, Banwell BL, Liu G, Waldman AT. Hospital admission rates for pediatric multiple sclerosis in the United States using the Pediatric Health Information System (PHIS). Mult Scler Relat Disord. 2016;9:5-10.

21. Bajer-Kornek B, Baumhackl U, Vass K. Epidemiology of paediatric-onset multiple sclerosis in Austria. Multiple sclerosis (Houndmills, Basingstoke, England). 2009;Conference:(var.pagings). 15 (9 Suppl S):S38.

22. Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, Robertson NP. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2012;18(1):45-54.
23. Ghezzi A, Deplano V, Faroni J, Grasso MG, Liguori M, Marrosu G, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Multiple sclerosis (Houndmills, Basingstoke, England). 1997;3(1):43-6.

24. Harding KE, Liang K, Cossburn MD, Ingram G, Hirst CL, Pickersgill TP, et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2013;84(2):141-7.

25. Sveinbjornsdottir S, Magnusson H, Benedikz JE. Multiple sclerosis in Iceland from 1900 to 2000: A total population study. Mult Scler Relat Disord. 2014;3(3):375-83.

26. Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Multiple sclerosis (Houndmills, Basingstoke, England). 1997;3(1):43-6.

27. Harding AE, Riordan-Eva P, Govan GG. Mitochondrial DNA diseases: genotype and phenotype in Leber's hereditary optic neuropathy. Muscle and Nerve Supplement. 1995;3:S82-4.

28. Wright K, Winkler MD, Newton BD, Sormani MP, Okuda DT. Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation. Neurology: Neuroimmunology and NeuroInflammation. 2017;4(6).

29. Bourne T, Waltz M, Casper TC, et al. Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population. J Neurol Sci. 2017;375:371-5.

30. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1):54-9.

31. Benson L, Healy B, Gorman M, Baruch N, Gholipour T, Musallam A, et al. Support for the relapse disability paradox: Higher relapse rates persist in paediatric compared to adult onset multiple sclerosis at six year follow-up. Multiple sclerosis (Houndmills,
32. Krysko, KM, O'Connor P. Quality of Life, Cognition and Mood in Adults with Pediatric Multiple Sclerosis. Can J Neurol Sci. 2016;43(3):368-74.

33. Van Der Vuurst De V, Van Pelt DE, Mescheriakova JY, Wong YY, Ketelslegers IA, Siepman DAM, et al. Disease course after CIS in children versus adults: A prospective cohort study. Multiple sclerosis (Houndmills, Basingstoke, England). 2016;Conference:(pp 101), 2016. Date of Publication: September 2016.):101.

34. van der Vuurst de Vries RM, van Pelt ED, Mescheriakova JY, Wong YY, Ketelslegers IA, Siepman TA, et al. Disease course after clinically isolated syndrome in children versus adults: a prospective cohort study. Eur J Neurol. 2017;24(2):315-21.

35. Carroll S, Chalder T, Hemingway C, Heyman I, Moss-Morris R. "It feels like wearing a giant sandbag." Adolescent and parent perceptions of fatigue in paediatric multiple sclerosis. Europ J Paediatr Neurol. 2016;20(6):938-45.

36. Stark W, Huppke P, Gartner J. Paediatric multiple sclerosis: the experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence. J Neurol. 2008;255 Suppl 6:119-22, 2008 Dec:22.

37. Huppke B, Ellenberger D, Rosewich H, Friede T, Gartner J, Huppke P. Clinical presentation of pediatric multiple sclerosis before puberty. Eur J Neurol. 2014;21(3):441-6.

38. Ruano L, Branco M, Portaccio E, et al. Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. Multiple sclerosis (Houndmills, Basingstoke, England). 2017::1352458517717341, 2017 Jun 01.

39. Mendibe M, Barcena J, Llarena C, et al. Childhood-and juvenile-onset multiple sclerosis: Descriptive analysis of a prospectively monitored, population-based cohort.
Multiple sclerosis (Houndmills, Basingstoke, England). 2009;Conference: (var.pagings). 15 (9 Suppl S):S165.

40. Marin SE, Banwell BB, Till C. Cognitive trajectories in 4 patients with pediatric-onset multiple sclerosis: serial evaluation over a decade. J Child Neurol. 2013;28(12):1577-86.

41. Boyd JR, MacMillan LJ. Experiences of children and adolescents living with multiple sclerosis. J Neurosci Nurs. 2005;37(6):334-42.

42. Krysko KM, O'Connor P. Quality of Life, Cognition and Mood in Adults with Pediatric Multiple Sclerosis. Can J Neurol Sci. 2016;43(3):368-74.

43. Lulu S, Julian L, Shapiro E, Hudson K, Waubant E. Treatment adherence and transitioning youth in pediatric multiple sclerosis. Mult Scler Relat Disord. 2014;3(6):689-95.

44. Marin SE, Banwell BB, Till C. Cognitive trajectories in 4 patients with pediatric-onset multiple sclerosis: serial evaluation over a decade. J Child Neurol. 2013;28(12):1577-86.

45. McCann KK, Farmer JE, Patel N. Childhood-onset multiple sclerosis and mood disorders: a case study. Child neuropsychol. 2004;10(2):102-16.

46. Mowry EM, Julian LJ, Im-Wang S, Chabas D, Galvin AJ, Strober JB, et al. Health-related quality of life is reduced in pediatric multiple sclerosis. Pediatr Neurol. 2010;43(2):97-102.

47. Macallister WS, Christodoulou C, Troxell R, Milazzo M, Block P, Preston TE, et al. Fatigue and quality of life in pediatric multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2009;15(12):1502-8.

48. Schreiner T, Ross C, Armstrong-Wells J. Parent-patient quality of life perception in children with Multiple Sclerosis. Ann Neurol. 2011;Conference:(var.pagings). 70 ():
49. Zafar AB, Ness J, Dowdy S, Avis K, Bashir K. Examining sleep, fatigue, and daytime sleepiness in pediatric multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England). 2012;18(4):481-8.

50. Baruch NF, O’Donnell EH, Glanz BI, Benedict RH, Musallam AJ, Healy BC, et al. Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2016;22(3):354-61.

51. Krysko KM, O'Connor PW. Quality of life, cognitive function and mood in young adults with pediatric-onset multiple sclerosis. Can J Neurol Sci. 2010;Conference: (var.pagings). 37 (3 Suppl 1):S14.

52. Zafar AB, Ness J, Dowdy S, et al. Examining sleep, fatigue, and daytime sleepiness in pediatric multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England). 2012;18(4):481-8.

53. Ostojic S, Stevanovic D, Jancic J. Quality of life and its correlates in adolescent multiple sclerosis patients. Mult Scler Relat Disord. 2016;10:57-62.

54. Ketelslegers IA, Catsman BCE, Boon M, et al. Fatigue and depression in children with multiple sclerosis and monophasic variants. Europ J Paediatr Neurol. 2010;14(4):320-5.

55. Uccelli MM, Traversa S, Trojano M, et al. Lack of information about multiple sclerosis in children can impact parents' sense of competency and satisfaction within the couple. J Neurol Sci. 2013;324(1-2):100-5.

56. Grover SA, Sawicki CP, Kinnett HD, et al. Physical Activity and Its Correlates in Youth with Multiple Sclerosis. J Pediatr. 2016;179:197-203.

57. Till C, Udler E, Ghassemi R, Narayanan S, Arnold DL, Banwell BL. Factors associated with emotional and behavioral outcomes in adolescents with multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England). 2012;18(8):1170-80.

58. Grover S A, Aubert BB, Fetco D, et al. Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis. Neurology. 2015;85(19):1663-9.

59. Baruch NF, O'Donnell EH, Glanz BI, et al. Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2016;22(3):354-61.

60. Goretti B, Ghezzi A, Portaccio E, et al. Psychosocial issue in children and adolescents with multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2010;31(4):467-70.

61. Amato MP, Goretti B, Ghezzi A, et al. Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. Neurology. 2014;83(16):1432-8.

62. Fuentes A, Collins DL, Garcia-Lorenzo D, Sled JG, Narayanan S, Arnold DL, et al. Memory performance and normalized regional brain volumes in patients with pediatric-onset multiple sclerosis. J Int Neuropsychol Soc. 2012;18(3):471-80.

63. Hosseini B, Flora DB, Banwell BL, Till C. Age of onset as a moderator of cognitive decline in pediatric-onset multiple sclerosis. J Int Neuropsychol Soc. 2014;20(8):796-804.

64. Banwell BL, Anderson PE. The cognitive burden of multiple sclerosis in children. Neurology. 2005;64(5):891-4.

65. Bigi S, Banwell B. Pediatric multiple sclerosis. J Child Neurol. 2012;27(11):1378-83.

66. Charvet LE, Beekman R, Amaduime N, Belman AL, Krupp LB. The Symbol Digit Modalities Test is an effective cognitive screen in pediatric onset multiple sclerosis (MS). J Neurol Sci. 2014;341(1-2):79-84.

67. Charvet LE, Cleary RE, Vazquez K, Belman AL, Krupp LB, MS USNfP. Social cognition
in pediatric-onset multiple sclerosis (MS). Multiple sclerosis (Houndmills, Basingstoke, England). 2014;20(11):1478-84.

68. Charvet LE, O'Donnell EH, Belman AL, Chitnis T, Ness JM, Parrish J, et al. Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. Multiple sclerosis (Houndmills, Basingstoke, England). 2014;20(11):1502-10.

69. Holland AA, Graves D, Greenberg BM, Harder LL. Fatigue, emotional functioning, and executive dysfunction in pediatric multiple sclerosis. Child neuropsychol. 2014;20(1):71-85.

70. Ross KA, Schwebel DC, Rinker J, et al. Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis. Neurology. 2010;75(23):2097-102.

71. Smerbeck AM, Parrish J, Serafin D, Yeh EA, Weinstock-Guttman B, Hoogs M, et al. Visual-cognitive processing deficits in pediatric multiple sclerosis. Multiple Sclerosis Journal. 2011;17(4):449-56.

72. Waldman A, Chahin S, Banwell B, Liu G, Balcer L. Binocular low-contrast acuity and the symbol digit modalities test improve the ability of the multiple sclerosis functional composite to predict disease in pediatric multiple sclerosis. Neurology. 2015;Conference:(var.pagings). 84 (no pagination), 2015. Date of Publication: 06 Apr 2015.).

73. Charvet, LE, Beekman R, Amadiume N, et al. The Symbol Digit Modalities Test is an effective cognitive screen in pediatric onset multiple sclerosis (MS). J Neurol Sci. 2014;341(1-2):79-84.

74. Charvet LE, O'Donnell EH, Belman AL, et al. Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. Multiple sclerosis (Houndmills, Basingstoke, England).
75. Charvet LE, Cleary RE, Vazquez K, et al. Social cognition in pediatric-onset multiple sclerosis (MS). Multiple sclerosis (Houndmills, Basingstoke, England). 2014;20(11):1502-10.

76. Fuentes A, Collins DL, Garcia LD, et al. Memory performance and normalized regional brain volumes in patients with pediatric-onset multiple sclerosis. J Int Neuropsychol Soc. 2012;18(3):471-80.

77. Waldman AT, Chahin S, Lavery AM, et al. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis. Mult Scler Relat Disord. 2016;10:73-8.

78. Till C, Ho C, Dudani A, et al. Magnetic resonance imaging predictors of executive functioning in patients with pediatric-onset multiple sclerosis. Arch Clin Neuropsychol. 2012;27(5):495-509.

79. Bigi S, Marrie RA, Till C, et al. The computer-based Symbol Digit Modalities Test: establishing age-expected performance in healthy controls and evaluation of pediatric MS patients. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2017;38(4):635-42.

80. Weier K, Till C, Fonov V, et al. Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2016;22(5):599-607.

81. Julian L, Serafin D, Charvet L, et al. Cognitive impairment occurs in children and adolescents with multiple sclerosis: Results from a United States network. J Child Neurol. 2013;28(1):102-7.
82. Weisbrot D, Charvet L, Serafin D, et al. Psychiatric diagnoses and cognitive impairment in pediatric multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2014;20(5):588-93.

83. Amato MP, Goretti B, Ghezzi A, Hakiki B, Niccolai C, Lori S, et al. Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. Neurology. 2014;83(16):1432-8.

84. Ketelslegers IA, Catsman-Berrevoets CE, Boon M, Eikelenboom MJ, Stroink H, Neuteboom RF, et al. Fatigue and depression in children with multiple sclerosis and monophasic variants. Europ J Paediatr Neurol. 2010;14(4):320-5.

85. Portaccio E, Goretti B, Lori S, Zipoli V, Centorrino S, Ghezzi A, et al. The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2009;15(5):620-6.

86. Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Portaccio E, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008;70(20):1891-7.

87. Goretti B, Ghezzi A, Portaccio E, Lori S, Zipoli V, Razzolini L, et al. Psychosocial issue in children and adolescents with multiple sclerosis. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2010;31(4):467-70.

88. Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Moiola L, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010;75(13):1134-40.

89. Konuskan B, Duzgun PG, Anlar B. Cognitive function in children with multiple sclerosis. DevMed Child Neurol. 2012;Conference:(var.pagings). 54 ((pp 134-135), 2012. Date of Publication: June 2012.):134-5.
90. Macallister WS, Christodoulou C, Troxell R, et al. Fatigue and quality of life in pediatric multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2009;15(12):1502-8.

91. Amato MP. Cognition in paediatric MS. J Neurol. 2014;Conference:(var.pagings). 261 (pp S475), 2014. Date of Publication: May 2014.:S475.

92. Toussaint DLC, Wong YYM, Van der Cammen-van ZMH, et al. Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis. Multiple sclerosis (Houndmills, Basingstoke, England). 2017;:1352458517706038, 2017 Apr 01.

93. Carroll S, Chalder T, Hemingway C, Heyman I, Moss-Morris R. Understanding fatigue in paediatric multiple sclerosis: A systematic review of clinical and psychosocial factors. DevMed Child Neurol. 2016;58(3):229-39.

94. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurology. 2007;6(9):773-81.

95. Ruano L, Branco M, Portaccio E, Goretti B, Niccolai C, Patti F, et al. Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. Multiple sclerosis (Houndmills, Basingstoke, England). 2017;:1352458517717341, 2017 Jun 01.

96. Krupp LB, Vieira MC, Boulos FC, et al. Review of the epidemiology and treatment landscape in pediatric multiple sclerosis in The United States. Value in Health. 2017;Conference:(5):A198-A9.

Tables
Table 1. PICOS criteria for inclusion and exclusion of studies
| Criteria          | Include                                                                 | Exclude                                                                 |
|------------------|--------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Population       | · MS patients <18 years of age                                            | · Studies not including MS years of age                                 |
|                  | · Studies considered relevant to North America and Europe                 | · Studies not considered North America and Europe                        |
| Intervention     | · Any MS intervention or none                                             | · No exclusion criteria                                                  |
| Comparators      | · Any or no comparators                                                   | · No exclusion criteria                                                  |
|                  | · Publications comparing pediatric and adult populations are of interest  |                                                                         |
| Outcomes         | · Studies reporting at least one of the following outcomes will be included: |                                                                         |
|                  |   o Clinical burden: relapse, expanded disability status score (EDSS) and other measures of disability, co-morbidities (including but not limited to depression, epilepsy, blindness or paralysis secondary to MS, fatigue, physical development, sexual development), medication adherence and persistence |                                                                         |
|                  |   o Humanistic Burden: cognitive functioning, school performance, attendance at school, cognitive decline, health-related quality of life |                                                                         |
|                  |   o Economic Burden: direct healthcare costs, hospital resource utilization, caregiver burden | · Studies not reporting any relevance listed                              |
|                  |                                                                         | · Studies reporting relevant outcomes, but in groups of mixed populations (e.g. children and adults with MS) without reporting data specifically for MS |
| Study Design     | · Observational studies, including prospective and retrospective cohort studies, cross-sectional studies, and cost-of-illness studies | · Systematic reviews, including RCTs randomized interventional studies |
|                  |   · Narrative reviews and expert opinions will be eligible in order to supplement the main searches and provide context for the findings from observational studies |   · Systematic reviews: analyses will be included at the title/abstract review stage, then excluded following hand searching of their references lists at the full-text stage |
|                  |   · Systematic reviews and meta-analyses will be included at the title/abstract review stage, then excluded following hand searching of their references lists at the full-text review stage |                                                                         |
| Other Considerations | · Only studies with abstracts or full-texts in English will be included    | · Studies not published in English                                         |
|                  | · Only studies on human subjects will be included                        | · Studies not on human subjects                                          |

Table 2. Incidence Data in North America and Europe
| Study                          | Region        | Year          | Age Group | Incidence                                      |
|-------------------------------|---------------|---------------|-----------|-----------------------------------------------|
| Wright et al. 2017(7)         | USA           | 2002-2012     | 0-18      | 0.57 cases per 100,000 population             |
| Manouchehrinia et al. 2015(18)| Sweden        | NR            | 0-16      | 0.77 per 1,000 person-years                   |
| Blinkenberg et al. 2013(9)    | Denmark       | 1979-2010     | 0-15      | 0.33 per 100,000 person-years                 |
| Dell’Avvento et al. 2016(10)  | Italy         | 2001-2012     | 0-11      | 0.68 per 100,000 children                    |
|                              |               |               | 0-14      | 0.54 per 100,000 children                    |
| Gudbjornsson et al. 2015(11)  | Iceland       | 1990-2009     | 0-17      | 0.45 per 100,000 person-years                 |
| Pohl et al. 2008(16)          | Germany       | 1997-1999     | 0-15      | 0.3 per 100,000 person-years                  |
|                              |               |               | 0-9       | 0.1 per 100,000 person-years                  |
|                              |               |               | 10-15     | 0.6 per 100,000 person-years                  |
| Reinhardt et al. 2014(17)     | Germany       | 2009-2011     | 0-15      | 0.64 per 100,000 person-years                 |
|                              |               |               | 0-10      | 0.09 per 100,000 person-years                 |
|                              |               |               | 11-13     | 1.10 per 100,000 person-years                 |
|                              |               |               | 14-15     | 2.64 per 100,000 person-years                 |
| Bizjak et al. 2017(14)        | Slovenia      | 1992-2017     | 0-18      | 0.66 per 100,000 children                     |
| Boesen et al. 2017(15)        | Denmark       | 1977-2015     | 0-17      | 0.79 per 100,000 person-years                 |
|                              |               | 2008-2015     | 0-17      | 0.88 per 100,000 person-years                 |

Table 3. Prevalence Data in North America and Europe
| Study                      | Region              | Year       | Age Group | Prevalence (% (95%CI) or cases per 100,000 persons) |
|----------------------------|---------------------|------------|-----------|--------------------------------------------------|
| Dilokthornsakul et al. 2016 (19) | USA     | 2012       | 0-4       | 0.2 (0-0.6) cases per 100,000                     |
|                           |                     |            | 5-9       | 1.1 (0.5-1.7) cases per 100,000                   |
|                           |                     |            | 10-14     | 2.3 (1.5-3.1) cases per 100,000                   |
|                           |                     |            | 15-19     | 14.6 (12.7-16.5) cases per 100,000               |
| Lavery et al. 2016 (20) USA 2004-2013 | USA     | 2004-2013  | <11       | 0.035 cases per 100,000                          |
|                           |                     |            | 11-15     | 0.256 cases per 100,000                          |
|                           |                     |            | >15       | 0.441 cases per 100,000                          |
|                           |                     |            | 0-15      | 0.159 cases per 100,000                          |
| Bajer-Korneck et al. 2009 (21) Austria | NR     |            | 0-17      | Symptom onset: 8.4% of all MS patients             |
|                           |                     |            |           | Diagnosis: 2.7% of all MS patients                 |
| Cossburn et al. 2012 (22) UK | NR     | 0-9        |           | 0.7% of all MS patients                           |
|                           |                     |            | 10-15     | 2.7% of all MS patients                           |
|                           |                     |            | 0-15      | 3.4% of all MS patients                           |
| Ghezzi. 1997(26) Gallarate, Italy | NR     | 0-16       |           | 4.4% of all MS patients                           |
|                           | Rome, Italy         |            |           | 5% of all MS patients                              |
|                           | Bari, Italy         |            |           | 3.4% of all MS patients                            |
|                           | Cagliari, Italy     |            |           | 7.9% of all MS patients                            |
| Harding et al. 2013 (27) UK Since 1985 | NR     | 0-9        |           | 0.3% of all MS patients                           |
|                           |                     |            | 10-15     | 2.5% of all MS patients                           |
|                           |                     |            | 16-17     | 2.6% of all MS patients                           |
|                           |                     |            | 0-17      | 5.4% of all MS patients                           |
| Manouchehrnia et al. 2015 (8) Sweden | NR     | 0-16       |           | 2.6% of all MS patients                           |
| Sveinbjorndottir et al. 2014 (25) Iceland | 1990-2000 | 0-17       |           | 9.6% of all MS patients                           |
| Wright et al. 2017 (28) USA Since 1985 | USA     |            | 0-18      | 4.65 cases per 100,000                            |

**Figures**
Figure 1

Search and Exclusion Process.
### Number of Publications on Pediatric MS Burden Outcomes

![Bar Chart showing number of publications on different outcomes](image)

#### Outcomes Evaluated

- **Epidemiology**
  - Incidence: 9 (North American), 9 (European)
  - Prevalence: 9 (North American), 9 (European)
  - Mortality: 1 (North American), 0 (European)

- **Disease Characteristics**
  - Disease Course: 36 (North American), 39 (European)
  - Relapse Rate: 20 (North American), 15 (European)
  - Disability: 47 (North American), 37 (European)

- **Humanistic Burden**
  - Quality of Life: 17 (North American), 17 (European)
  - Mood: 0 (North American), 22 (European)

- **Economic Burden**
  - Cognitive Function: 4 (North American), 4 (European)

#### Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- Additional File 4.xlsx
- Additional File 3.xlsx
- Additional File 6.xlsx
- Additional File 2.xlsx
- Additional File 1.docx
- Additional File 5.xlsx